Closing Thoughts on Evolving Antibody-Drug Conjugate Landscape
The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.
Educating Community Specialists on Evolving Treatment Landscape
Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.
Future Outlook for Treating Breast and Lung Cancers
Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.
Future Directions in Gastric Cancer Treatment
Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.
Treatment Considerations With TROP2-Targeted Therapy
Clinical insights on best practices for treating patients with TROP2-targeted therapy.
TROP2-Targeting Antibody-Drug Conjugates
The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.
Approved Antibody-Drug Conjugates in Breast, Lung, and GI Malignancies
A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.
Managing T-DXd Toxicities in Gastric Cancer
Insights on managing antibody-drug conjugate toxicities for patients with gastric cancer.
Gastric Cancer Treatment: T-DXd
A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.
Management of ADC Toxicities in Lung Cancer
A nurse practitioner provides insights on toxicity management strategies for patients with lung cancer who are receiving antibody-drug conjugates.
Antibody-Drug Conjugates in Lung Cancer
A medical oncologist reviews the antibody-drug conjugate landscape in lung cancer.
Toxicity Management for T-DM1 and T-DXd in Breast Cancer
Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].
Antibody-Drug Conjugates in Breast Cancer
A breast medical oncologist provides insights on antibody-drug conjugates in the breast cancer space and discusses ongoing research.
Best Practices for Patient Education Surrounding Cancer Treatment
The expert panel has a comprehensive discussion about best practices for patient education and the barriers to effective testing.
Molecular Testing Considerations in Cancer Treatment
Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.
Biomarker Testing in Gastrointestinal and Lung Cancers
Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.
Molecular Testing in Breast Cancer
A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.
Mechanisms of Action of Antibody-Drug Conjugates
The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.
Overview of Antibody-Drug Conjugates (ADCs)
A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).
Dr. Musher on Immunotherapy Versus TKIs in HCC
Benjamin Leon Musher, MD, discusses immunotherapy versus TKIs in hepatocellular carcinoma.
Dr. Musher on Current Therapies for HCC
Benjamin Leon Musher, MD, discusses the current treatment options for patients with hepatocellular carcinoma.
Dr. Musher Discusses the Role of Regorafenib in Advanced HCC
Benjamin Leon Musher, MD, associate professor of medicine, hematology and oncology, at Baylor College of Medicine, discusses the role of regorafenib in the treatment of patients with advanced hepatocellular carcinoma.
Dr. Musher on Investigational Combination Therapies in HCC
Benjamin Leon Musher, MD, associate professor of medicine, hematology and oncology, at Baylor College of Medicine, discusses emerging combination therapies in hepatocellular carcinoma (HCC).
Endocrine Therapy Response Status Is Necessary for Treatment Planning in HR+/HER2– Early Breast Cancer
Neoadjuvant Nivolumab Plus Carboplatin/Paclitaxel Elicits High pCR Rates in Early-Stage TNBC
Dr Schmid on the Use of Perioperative Pembrolizumab in TNBC
Dr Khan on Optimizing Local Therapy Using MRI and a 12-Gene Expression Assay in DCIS
2 Clarke Drive Cranbury, NJ 08512